Fadi Haddad

3.8k total citations
190 papers, 1.7k citations indexed

About

Fadi Haddad is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Fadi Haddad has authored 190 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Hematology, 72 papers in Public Health, Environmental and Occupational Health and 62 papers in Genetics. Recurrent topics in Fadi Haddad's work include Chronic Myeloid Leukemia Treatments (71 papers), Acute Lymphoblastic Leukemia research (66 papers) and Chronic Lymphocytic Leukemia Research (58 papers). Fadi Haddad is often cited by papers focused on Chronic Myeloid Leukemia Treatments (71 papers), Acute Lymphoblastic Leukemia research (66 papers) and Chronic Lymphocytic Leukemia Research (58 papers). Fadi Haddad collaborates with scholars based in United States, Lebanon and France. Fadi Haddad's co-authors include Hampig Raphaël Kourié, Roland Eid, Hagop M. Kantarjian, Elias Jabbour, Nicholas J. Short, Vijay H. Shah, John A. Frangos, Albert Mennone, Guillermo García‐Cardeña and Roberto J. Groszmann and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Fadi Haddad

158 papers receiving 1.7k citations

Peers

Fadi Haddad
Joon Ho Moon South Korea
Massimo Iacobelli United States
Shigeru Horita Japan
Jenny N. Poynter United States
N. Tubiana-Mathieu France
Fitzroy W. Dawkins United States
Ishmael Jaiyesimi United States
Frank S. Fan Taiwan
Frederick Richards United States
Uğur Çoşkun Türkiye
Joon Ho Moon South Korea
Fadi Haddad
Citations per year, relative to Fadi Haddad Fadi Haddad (= 1×) peers Joon Ho Moon

Countries citing papers authored by Fadi Haddad

Since Specialization
Citations

This map shows the geographic impact of Fadi Haddad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadi Haddad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadi Haddad more than expected).

Fields of papers citing papers by Fadi Haddad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadi Haddad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadi Haddad. The network helps show where Fadi Haddad may publish in the future.

Co-authorship network of co-authors of Fadi Haddad

This figure shows the co-authorship network connecting the top 25 collaborators of Fadi Haddad. A scholar is included among the top collaborators of Fadi Haddad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fadi Haddad. Fadi Haddad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kantarjian, Hagop M., Yifan Zhai, Vivian G. Oehler, et al.. (2025). Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research. Cancer. 131(8). e35832–e35832. 2 indexed citations
2.
Sharma, Padmanee, Denái R. Milton, Alison Gulbis, et al.. (2025). Long-Term Results of Ipilimumab Alternating with Lenalidomide in Patients with Relapsed Lymphoma Who Underwent Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 31(2). S427–S428.
3.
Short, Nicholas J., Elias Jabbour, Walid Macaron, et al.. (2025). Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood Cancer Journal. 15(1). 169–169.
4.
Kantarjian, Hagop M., Nicholas J. Short, Nitin Jain, et al.. (2025). Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia. American Journal of Hematology. 100(3). 402–407. 6 indexed citations
5.
6.
Kantarjian, Hagop M., Fadi Haddad, Nicholas J. Short, et al.. (2024). Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia. Blood. 144(Supplement 1). 6605–6605. 1 indexed citations
7.
Kantarjian, Hagop M., David McCue, Fadi Haddad, et al.. (2024). Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leukemia & lymphoma. 65(9). 1325–1334. 4 indexed citations
8.
Senapati, Jayastu, Hagop M. Kantarjian, Fadi Haddad, et al.. (2024). Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation. American Journal of Hematology. 100(2). 249–259. 3 indexed citations
9.
Jabbour, Elias, Fadi Haddad, Koji Sasaki, et al.. (2024). Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 130(15). 2652–2659. 8 indexed citations
10.
Bazarbashi, Shouki, et al.. (2024). The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts. Journal of Blood Medicine. Volume 15. 171–189. 2 indexed citations
11.
Kantarjian, Hagop M., Nicholas J. Short, Fadi Haddad, et al.. (2024). Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology. 42(36). 4246–4251. 23 indexed citations
12.
13.
14.
Jabbour, Elias, Koji Sasaki, Fadi Haddad, et al.. (2023). The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors. American Journal of Hematology. 98(4). 658–665. 15 indexed citations
15.
Jabbour, Elias, Fadi Haddad, Nicholas J. Short, et al.. (2023). Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 143(5). 417–421. 25 indexed citations
16.
Short, Nicholas J., Elias Jabbour, Shilpa Paul, et al.. (2023). Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24(4). e168–e173. 11 indexed citations
17.
Short, Nicholas J., Elias Jabbour, Walid Macaron, et al.. (2023). Ultrasensitive NGS MRD assessment in Ph+  ALL : Prognostic impact and correlation with RT‐PCR for BCR::ABL1. American Journal of Hematology. 98(8). 1196–1203. 37 indexed citations
18.
Richa, Sami, et al.. (2022). Social representations of intellectual disability; a comparison between cultures. L Encéphale. 49(5). 466–473. 1 indexed citations
19.
Richard‐Carpentier, Guillaume, Hagop M. Kantarjian, Guilin Tang, et al.. (2021). Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances. 5(23). 5415–5419. 25 indexed citations
20.
Haddad, Fadi, et al.. (2021). The Impact of Disasters on Cancer Care in Lebanon. Future Oncology. 17(6). 629–631. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joon Ho Moon Breakdown of academic impact, for papers by Massimo Iacobelli Breakdown of academic impact, for papers by Shigeru Horita Breakdown of academic impact, for papers by Jenny N. Poynter Breakdown of academic impact, for papers by N. Tubiana-Mathieu Breakdown of academic impact, for papers by Fitzroy W. Dawkins Breakdown of academic impact, for papers by Ishmael Jaiyesimi Breakdown of academic impact, for papers by Frank S. Fan Breakdown of academic impact, for papers by Frederick Richards Breakdown of academic impact, for papers by Uğur Çoşkun
Rankless by CCL
2026